|
|
|
|
| LEADER |
01000caa a2200265 4500 |
| 001 |
OLC1994804963 |
| 003 |
DE-627 |
| 005 |
20230516154528.0 |
| 007 |
tu |
| 008 |
170721s2017 xx ||||| 00| ||eng c |
| 024 |
7 |
|
|a 10.1158/1538-7445.SABCS16-OT1-02-09
|2 doi
|
| 028 |
5 |
2 |
|a PQ20170721
|
| 035 |
|
|
|a (DE-627)OLC1994804963
|
| 035 |
|
|
|a (DE-599)GBVOLC1994804963
|
| 035 |
|
|
|a (PRQ)crossref_primary_10_1158_1538_7445_SABCS16_OT1_02_090
|
| 035 |
|
|
|a (KEY)0108894720170000077000400000abstractot10209aphase2randomizeddoubleblindedcontr
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
4 |
|a 610
|q DNB
|
| 084 |
|
|
|a XA 10000
|q AVZ
|2 rvk
|
| 084 |
|
|
|a 44.81
|2 bkl
|
| 100 |
1 |
|
|a Hamilton, E
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 700 |
1 |
|
|a Borges, V
|4 oth
|
| 700 |
1 |
|
|a Murthy, R
|4 oth
|
| 700 |
1 |
|
|a Anders, C
|4 oth
|
| 700 |
1 |
|
|a Cameron, D
|4 oth
|
| 700 |
1 |
|
|a Carey, L
|4 oth
|
| 700 |
1 |
|
|a Müller, V
|4 oth
|
| 700 |
1 |
|
|a Curigliano, G
|4 oth
|
| 700 |
1 |
|
|a Gelmon, K
|4 oth
|
| 700 |
1 |
|
|a Hortobagy, G
|4 oth
|
| 700 |
1 |
|
|a Krop, I
|4 oth
|
| 700 |
1 |
|
|a Loibl, S
|4 oth
|
| 700 |
1 |
|
|a Pivort, X
|4 oth
|
| 700 |
1 |
|
|a Pegram, M
|4 oth
|
| 700 |
1 |
|
|a Slamon, D
|4 oth
|
| 700 |
1 |
|
|a Hurvitz, S
|4 oth
|
| 700 |
1 |
|
|a Tsai, M
|4 oth
|
| 700 |
1 |
|
|a Winer, E
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|t Cancer research
|d Birmingham, Ala. [u.a.] : AACR, 1941
|g 77(2017), 4 Supplement
|w (DE-627)12906775X
|w (DE-600)1432-1
|w (DE-576)014399199
|x 0008-5472
|7 nnns
|
| 773 |
1 |
8 |
|g volume:77
|g year:2017
|g number:4 Supplement
|
| 856 |
4 |
1 |
|u http://dx.doi.org/10.1158/1538-7445.SABCS16-OT1-02-09
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_OLC
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a SSG-OLC-DE-84
|
| 912 |
|
|
|a GBV_ILN_55
|
| 912 |
|
|
|a GBV_ILN_62
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2219
|
| 912 |
|
|
|a GBV_ILN_4012
|
| 912 |
|
|
|a GBV_ILN_4219
|
| 936 |
r |
v |
|a XA 10000
|
| 936 |
b |
k |
|a 44.81
|q AVZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 77
|j 2017
|e 4 Supplement
|
